NCT07532148 2026-04-15
Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Chong Kun Dang Pharmaceutical
Phase 1 Not yet recruiting
Clinical Trials
26 trialsNCT02577926 2025-06-10
Ruxo-BEAT
RWTH Aachen University
Phase 2 Active not recruiting
NCT04049331 2025-03-11
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
Seattle Institute for Biomedical and Clinical Research
Phase 2 Recruiting
NCT05054751 2024-10-10
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Genor Biopharma Co., Ltd.
Phase 3 Completed
NCT04500587 2024-09-19
Phase 1 First in Human Study of ZN-d5 as a Single Agent
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1 Completed
NCT05199337 2024-09-19
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05682170 2024-09-19
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT05883683 2024-07-24
MSPM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not yet recruiting
NCT05189171 2024-06-28
MODEL-CRC
Xilis, Inc.
Completed
NCT05758610 2024-05-08
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
Shengke Pharmaceuticals (Jiangsu) Limited, China
Phase 1 Recruiting
NCT04197986 2024-03-13
PROOF302
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT04840784 2023-10-11
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
Shengke Pharmaceuticals (Jiangsu) Limited, China
Phase 1 Terminated
NCT06055348 2023-09-26
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Unknown
NCT05913141 2023-06-22
PDO/PDO-TIL/PDOTS for Drug Screen
Shanghai Zhongshan Hospital
Recruiting
NCT04972422 2021-09-05
A Phase 1b Study of ZN-c3 in Chinese Subjects
Zentera Therapeutics HK Limited
Phase 1 Unknown
NCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
NCT02032784 2020-07-16
Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
AdventHealth
Phase 4 Terminated
NCT03236974 2020-02-06
D6090C00002
AstraZeneca
Phase 1 Completed
NCT02538471 2019-12-09
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT04121039 2019-10-09
Study of the Apatinib Combine With POF Versus POF in Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04088110 2019-09-12
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
Fuzhou General Hospital
Phase 2 Unknown
NCT01403610 2019-07-24
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT03910712 2019-04-10
Pyrotinib
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02828111 2019-01-08
BCC
PellePharm, Inc.
Phase 2 Completed
NCT00582660 2017-06-15
UAB0040
University of Alabama at Birmingham
Phase 2 Completed
NCT01893879 2017-05-18
PCTTPL
Stanford University
Phase NA Terminated